CTOs on the Move

Edgewise Therapeutics

www.edgewisetx.com

 
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it`s Series B financing round which will support the advancement of Edgewise Therapeutic`s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company`s pipeline. The company`s leadership team has founded multiple biotechnology ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Edgewise Therapeutics raised $95M on 12/08/2020

Similar Companies

CuraScript

CuraScript is one of the nation's largest providers of specialty injectable and oral medications. CuraScript has been in the specialty pharmacy business since 1989. Between 1994 and August 1, 2000, the company operated as Coram Prescription Services

AlgoRx Pharmaceuticals

AlgoRx Pharmaceuticals is a Wilton, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Algenix

Algenix is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Modern Recovery

[et_pb_section fb_built="1" specialty="on" custom_padding_last_edited="on|tablet" _builder_version="4.6.6" _module_preset="default" background_color="#9e9e9e"

Albireo Pharma

Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo`s lead product candidate, A4250, is directed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo`s clinical pipeline also includes two Phase 2 product candidates. Albireo`s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden.